US 11,883,432 B2
Chimeric antigen receptor system with adaptable receptor specificity
Jill Marinari Carton, Philadelphia, PA (US); Michael Francis Naso, Philadelphia, PA (US); Luis Ghira Borges, Philadelphia, PA (US); John Wheeler, Philadelphia, PA (US); and Andrew Devaney, Philadelphia, PA (US)
Assigned to CENTURY THERAPEUTICS, INC., Philadelphia, PA (US)
Filed by CENTURY THERAPEUTICS, INC., Philadelphia, PA (US)
Filed on Dec. 17, 2021, as Appl. No. 17/554,062.
Claims priority of provisional application 63/127,587, filed on Dec. 18, 2020.
Prior Publication US 2022/0193133 A1, Jun. 23, 2022
Int. Cl. A61K 39/00 (2006.01); A61K 35/17 (2015.01); C12N 5/0783 (2010.01)
CPC A61K 35/17 (2013.01) [C12N 5/0636 (2013.01)] 13 Claims
 
1. A universal chimeric antigen receptor system having an adaptable receptor specificity component (arCAR), comprising
(i) an immune effector cell having a chimeric antigen receptor comprising a first polypeptide comprising:
(a) an extracellular tag-binding domain,
(b) a transmembrane domain, and
(c) at least one intracellular signaling domain; and
(ii) a second soluble polypeptide comprising:
(a) an antigen-binding domain that binds to at least one antigen on a target cell, and
(b) a tag that is recognized by the extracellular tag-binding domain;
wherein:
the tag comprises the polypeptide sequence of SEQ ID NO: 112, and the extracellular tag-binding domain comprises the polypeptide sequence of SEQ ID NO: 129; or
the tag comprises the polypeptide sequence of SEQ ID NO: 129, and the extracellular tag-binding domain comprises the polypeptide sequence of SEQ ID NO: 112.